I
INMUNE BIO INC
NASDAQ: INMB (INmune Bio Inc.)
Last update: 23 minutes ago1.38
-0.07 (-4.83%)
| Previous Close | 1.45 |
| Volume | 203,566 |
| Price / Book | 1.96 |
| 52 Weeks Range |
| Operating Margin (TTM) | -19,810.00% |
| Diluted EPS (TTM) | -1.93 |
| Quarterly Revenue Growth (YOY) | 257.10% |
| Total Debt/Equity (MRQ) | 1.17% |
| Current Ratio (MRQ) | 2.64 |
| Operating Cash Flow (TTM) | -32.71 M |
| Levered Free Cash Flow (TTM) | -18.16 M |
| Return on Assets (TTM) | -61.33% |
| Return on Equity (TTM) | -139.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | INmune Bio Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.69 |
Select this tab to load the latest available analysis.
|
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 24.61% |
| % Held by Institutions | 27.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aqr Capital Management Llc | 30 Jun 2026 | 662,218 |
| Raymond James Financial Inc | 30 Jun 2026 | 212,995 |
| Millennium Management Llc | 30 Jun 2026 | 159,559 |
| Westside Investment Management, Inc. | 30 Jun 2026 | 108,300 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |